printemailclick to share buttonfacebooktwitterlinkedin
Assessment Statistics
 

Measuring the effect of the clinical trials policy is a priority for us and the Ministry of Health and Long-Term Care. We will be developing an evaluation framework to analyze the implementation of the policy and the effects on the cancer drug funding programs.

We are committed to transparency and will continue to publish clinical trial assessment outcomes and policy evaluation metrics on a regular basis.


Clinical trial assessment turnaround times

Turnaround Times
Percentage of assessments evaluated within 30 days 92% 280
Percentage of assessments evaluated between 31-60 days 8% 23

Figure description

This figure is titled 'Clinical trial assessment turnaround times' and is made up of a single pie chart. The turnaround times are measured in calendar days. They do not include the time when additional information is requested from the applicant.

The pie chart is made up of 2 slices. The first slice respresents the percentage of assessments evaluated within 30 days which is 92%. The second slice represents the percentage of assessments evaluated between 31 to 60 days which is 8%.



Clinical trial assessment turnaround times

Systemic Treatment-Quality Based Program Alignment
Aligned to ST-QBP definition of a clinical trial 95% 288
Not Aligned to ST-QBP definition of a clinical trial 5% 15

Figure description

This figure is titled 'Distribution of clinical trial assessment outcomes that receive funding for the administration and delivery of systemic treatment through Systemic Treatment-Quality Based Program (ST-QBP)' and is made up of a single pie chart.

The pie chart is made up of 2 slices. The first slice respresents the percentage of assessments aligned to ST-QBP definition of a clinical trial which is 95%. The second slice represents the percentage of assessments not aligned to ST-QBP definition of a clinical trial which is 5%.



Clinical trial assessment turnaround times

Provincial Drug Reimbursement Program Alignment
Aligned for the purpose of drug funding 92% 280
Partially Aligned for the purpose of drug funding 6% 18
Not Aligned for the purpose of drug funding 2% 5

Figure description

This figure is titled 'Distribution of clinical trial assessment outcomes for the purpose of public drug funding' and is made up of a single pie chart.

The pie chart is made up of 3 slices. The first slice respresents the percentage of assessments aligned for the purpose of drug funding which is 92%.

The second slice represents the percentage of assessments partially aligned for the purpose of drug funding, which is 6%. Some clinical trial applications request assessment for multiple publicly funded cancer drugs where some of the drugs are used in accordance with the existing drug funding policy i.e. "aligned" and some of the drugs are not used in accordance with the existing drug funding policy i.e. "not aligned". These clinical trial assessments are “partially aligned”.

The third slice represents the percentage of assessments not aligned for the purpose of drug funding which is 2%.


Last modified: Tue, Sep 05, 2017
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?

YesNo